Evidence-Based Oncology > February

Evidence-Based Oncology – February

March 12, 2012 – Lee N. Newcomer, MD, MHA
Radical Changes in Payment Incentives and Elimination of Low-Value Care
March 12, 2012 – Michael Synder, BA; Lee Goldberg, MBA; and Tracey Ryan, M.Eng
Health Plans Continue to Seek Methods to Curtail Cancer Costs
March 12, 2012 – Michael P. Link, MD
Grim Reality Is a Bitter Pill to Swallow: Interview with Michael P. Link, MD, ASCO President
March 12, 2012 – Tek Okon, MBA; and Lee Schwartzberg, MD, FACP
The Challenges Facing Oncologists Are Formidable
March 12, 2012 – A. Mark Fendrick, MD; and Jonas de Souza, MD
Insights Into Value-Based Insurance Design in Oncology
March 12, 2012 – Jennifer Klem, PhD; Stanton R. Mehr; and Marj Pestil Zimmerman, BSPharm
A New Era in Targeted Treatment Has Begun
March 16, 2012 – Cheryl Sarfaty
Why Oncologists Must Tailor Clinical Features to Their Needs
March 16, 2012 – Laura Mortkowitz
Promise and Pitfalls Along the Path to Personalized Care
March 16, 2012
The Duke Cancer Institute
March 16, 2012
To help oncology providers better understand drug mechanisms of action, and the economic implications of their use.
March 16, 2012
Review of the most recent evidence-based literature discussing breast, colorectal, lung, and ovarian cancers, in addition to melanoma and multiple myeloma.
March 16, 2012 – Kim L. Farina, PhD
How Much Do We Spend and How Can We Spend It Better?
March 19, 2012 – Kim L. Farina, PhD
Metabolomics, Proteomics, and Epigenetics
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!